Elevance Health (ELV) reported Q4 adjusted earnings Thursday of $3.84 per diluted share, down from $5.62 a year earlier.
Analysts surveyed by FactSet expected $3.81.
Total revenue for the quarter ended Dec. 31 was $45.44 billion, compared with $42.65 billion a year earlier.
Analysts surveyed by FactSet expected $44.92 billion.
For 2025, the company said it expects adjusted diluted EPS in the range of $34.15 to $34.85. A single analyst polled by FactSet expects $34.52.
Shares were up more than 4% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.